Use of terlipressin in the treatment of Hepatorenal syndrome: Intravenous infusion versus intravenous boluses; An Open Label, Pilot, Randomized Controlled Study

Abstract

Introduction: The purpose of this study was to evaluate the role of Terlipressin in the management of Hepatorenal Syndrome, focusing on the efficacy of its infusion and bolus regimens.
Objectives: To determine the efficacy and safety of Terlipressin intravenous infusion and bolus regimens in treating Hepatorenal Syndrome.
Materials & Methods: The study employed an open-label, randomized controlled trial design. A total of 56 patients with hepatorenal syndrome were randomly assigned to two groups. The infusion regimen of terlipressin was administered to the TERLI-I group, while the bolus regimen was given to the TERLI-B group. The drug response and its adverse effects were analyzed.
Result: Among the 56 patients, 83.9% responded to the treatment. In the TERLI-I group, 71.4% had a complete response, 14.2% had a partial response, and 14.2% were non-responders. In the TERLI-B group, 60.7% had a complete response, 21.4% had a partial response, and 17.8% were non-responders. Overall, the response to treatment (partial plus complete response) was observed in 85.7% of the TERLI-I group and 82.1% of the TERLI-B group. No significant treatment-related adverse events were observed.
Conclusion: Terlipressin remains the standard of care for the management of patients with hepatorenal syndrome. Both administration regimens were equally effective, with no significant adverse effects.